A study revealed that pioglitazone was significantly better at alleviating insulin resistance and inferior at improving β-cell function compared with DPP-4 inhibitors in patients with T2DM under similar glycemic control [23]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.